Compare · DAVI vs WST
DAVI vs WST
Side-by-side comparison of Davion Healthcare Plc (DAVI) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DAVI and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $27.85B, about 700.6x DAVI ($39.8M).
- WST has been more active in the news (7 items in the past 4 weeks vs 1 for DAVI).
- WST has more recent analyst coverage (20 ratings vs 0 for DAVI).
- Company
- Davion Healthcare Plc
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $39.8M
- $27.85B
- 1M return
- -
- +10.09%
- 1Y return
- -
- +45.11%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 7
- Recent ratings
- 0
- 20
Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments. The Company's flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion's broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare. Davion's growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group's product portfolio and commercial, manufacturing and distribution capabilities.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest DAVI
Latest WST
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- West to Participate in Upcoming Investor Conference
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Reports Third-Quarter 2026 Results
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Declares Quarterly Dividend
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea